Why the study?
Anthracycline usage is linked to unpredictable cardiovascular adverse events, making the identification of vulnerable populations and risk factors critical to reduce their occurrence.
Do specific clinical risk factors (hypertension, radiation therapy, diabetes, smoking, age) increase the risk of cardiovascular adverse events in lymphoma patients receiving anthracycline-based chemotherapy?
Do specific clinical risk factors (hypertension, radiation therapy, diabetes, smoking, age) increase the risk of cardiovascular adverse events in lymphoma patients receiving anthracycline-based chemotherapy?
In lymphoma patients receiving anthracycline chemotherapy, baseline hypertension, prior radiation, diabetes, smoking, and older age significantly increase the risk of cardiovascular adverse events, highlighting the need for targeted monitoring in these high-risk subgroups.
Supports risk-adapted cardiac monitoring in anthracycline-treated lymphoma patients with hypertension or diabetes; extends observational evidence for risk stratification.
Anthracycline usage has been linked to cardiovascular adverse events (CAEs), which is unpredictable. It is critical to identify the characteristics of vulnerable populations and risk factors in order to reduce the occurrence of CAEs. This meta-analysis aimed to assess the correlation between various risk factors and CAEs induced by anthracyclines. We systematically searched for studies from PubMed, Cochrane, Embase, and assessed the publication bias. Anthracyclines, hypertension, radiation therapy, diabetes, smoking, age, gender, hyperlipidemia, and obesity were meta-analyzed using a fixed or random effects model. Sixteen studies were included in this meta-analysis. The results showed that pooled relative ratio for CAEs was 1.69 (95% CI: 1.39–2.06, p<0.001) for anthracyclines, and that risk factors for CAEs caused by anthracyclines included hypertension (RR = 2.15, 95% CI: 1.53–3.01, p < 0.001), radiation therapy (RR = 1.71, 95% CI: 1.19–2.47, p < 0.001), diabetes (RR = 1.57, 95% CI: 1.20–2.06, p<0.001), smoking (RR = 1.35, 95% CI: 0.96–1.88, p < 0.05), and age (RR = 1.16, 95% CI: 1.07–1.26, p < 0.001). In addition, BMI > 25 kg/m2 (RR = 1.34, 95% CI: 1.08–1.67, p = 0.470), gender (RR = 1.17, 95% CI: 1.06–1.2, p = 0.350), and hyperlipidemia (RR = 1.10, 95% CI: 0.91–1.34, p = 0.327) was not significantly associated with CAEs caused by anthracyclines. Our research findings indicate that patients with a history of hypertension, radiation therapy, diabetes, smoking, and elderly individuals are at an elevated risk of cardiovascular disease in the process of administration of anthracycline drugs. Consequently, careful case selection and condition monitoring are important in the treatment process. Patients with comorbidities are more prone to suffering from CAEs with anthracycline based chemotherapy, and the risk factors are arranged clockwise in a descending order: hypertension, radiation therapy, diabetes, smoking, age. BMI>25 kg/m2, gender, and hyperlipidemia are not significant associated with CAEs with anthracycline based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: